Apparently, South Korea's KOSPI index, plunged over 8% - its worst single-day drop since 1997 - triggering a 20-minute trading halt due to circuit breakers, erasing about $270 billion in market value. Triggered by escalating Middle East tensions, including threats to the Strait of Hormuz, the crash stems from surging oil prices (Brent near $85/barrel) hitting South Korea's import-dependent economy, while chip stocks like Samsung fell sharply amid global sell-offs. Despite the panic, sectors like defense and shipping gained on safe-haven demand, underscoring how geopolitical shocks amplify volatility in export-reliant markets; this event aligns with broader Asian declines and fuels recession fears worldwide.

I checked prior discussions on MRK and PFE before posting. We’ve covered both Pfizer and Merck extensively since 2023 across various threads, and a new post in those would likely get buried or lack context. MRK and PFE report earnings this week and next, respectively. Both stocks have been climbing steadily, mirroring gains in XLV (Health Care Select Sector SPDR Fund) and XBI (SPDR S&P Biotech ETF). It seems they’re finally attracting buyers. Both companies face a common challenge: patent expirations. To address this, they’re actively acquiring other firms to bolster their pipelines. I’m looking forward to their earnings reports. Thoughts on their outlook or recent moves?

I ended up with 200 shares of PYPL and I am underwater. Have been listening to the news and apparently PYPL is joining with Coinbase so I am holding on tight. Any thoughts?

It looks and feels like they finally shook off all weak hands. I started buying.